CAS 155974-00-8|Ivabradine
Introduction：Basic information about CAS 155974-00-8|Ivabradine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Ivabradine | ||
|---|---|---|---|
| CAS Number | 155974-00-8 | Molecular Weight | 468.585 |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 626.9±55.0 °C at 760 mmHg |
| Molecular Formula | C27H36N2O5 | Melting Point | / |
| MSDS | / | Flash Point | 332.9±31.5 °C |
Names
| Name | ivabradine |
|---|---|
| Synonym | More Synonyms |
Ivabradine BiologicalActivity
| Description | Ivabradine is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine reduces dose-dependently heart rate without modification of blood pressure. Ivabradine shows anticonvulsant, anti-ischaemic and anti-anginal activity[1][2][3][4]. |
|---|---|
| Related Catalog | Research Areas >>Cardiovascular DiseaseSignaling Pathways >>Membrane Transporter/Ion Channel >>HCN Channel |
| In Vivo | Ivabradine (1, 10, 20 mg/kg; i.p.) shows anticonvulsant and neuroprotective action in mice[3]. Ivabradine (5, 10, 20 mg/kg;p.o.; daily for 1 weeks) lowers heart rate in mice with enhanced sympathoadrenergic activities[4]. Animal Model: 25-30 g, 6 weeks male Swiss mice[3] Dosage: 1, 10, 20 mg/kg Administration: I.p.; for 3 days Result: Attenuated PTZ- and PICRO-induced seizures while presented an antioxidant effect in allbrain areas studied, and reduced cleaved caspase-3 expression in the CA1 and DG region of PICRO- and PTZ-treated mice, respectively. Animal Model: 3-4 months transgenic (TG) mice with cardiac-restricted overexpression of b2AR[4] Dosage: 5, 10, 20 mg/kg Administration: P.o; daily for 1 weeks Result: Reduced the maximal HR increase in response to the b-agonist isoproterenol, without modifying the response of contractile parameters at 10 mg/kg. |
| References | [1]. Tardif JC, et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005 Dec;26(23):2529-36. [2]. Mulder P, et al. Heart rate slowing for myocardial dysfunction/heart failure. Adv Cardiol. 2006;43:97-105. [3]. Cavalcante TMB, et al. Ivabradine possesses anticonvulsant and neuroprotective action in mice. Biomed Pharmacother. 2019 Jan;109:2499-2512. [4]. Du XJ, et al. I(f) channel inhibitor ivabradine lowers heart rate in mice with enhanced sympathoadrenergic activities. Br J Pharmacol. 2004 May;142(1):107-12. |
Chemical & Physical Properties
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 626.9±55.0 °C at 760 mmHg |
| Molecular Formula | C27H36N2O5 |
| Molecular Weight | 468.585 |
| Flash Point | 332.9±31.5 °C |
| Exact Mass | 468.262421 |
| PSA | 60.47000 |
| LogP | 3.69 |
| Vapour Pressure | 0.0±1.8 mmHg at 25°C |
| Index of Refraction | 1.560 |
| InChIKey | ACRHBAYQBXXRTO-OAQYLSRUSA-N |
| SMILES | COc1cc2c(cc1OC)CC(=O)N(CCCN(C)CC1Cc3cc(OC)c(OC)cc31)CC2 |
Synonyms
| Ivabradine [INN] |
| 3-[3-({[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino)propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one |
| [14C]-Ivabradine |
| 3-{3-[{[(7S)-3,4-dimethoxybicyclo[4,2,0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino]-propyl}-7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one |
| UNII-3H48L0LPZQ |
| Ivabradine |
| 3-(3-((((7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one |
| Procoralan |
| 2H-3-Benzazepin-2-one, 3-[3-[[[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy- |
| 3-{3-[{[(7S)-3,4-Dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino]propyl}-7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one |
| Corlanor |
| 3-[3-[[(7S)-3,4-dimethoxy-7-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one |
